Flurbiprofen
Chronic Pain Syndrome
Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Beijing Tiantan Hospital
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06531837CT.gov Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Pain Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Flurbiprofen (this asset) | Beijing Tiantan Hospital | N/A | D · 30 |
| (±)-Tramadol | EMS | P4 | BBB |
| Methadone | Cari Health Inc. | P4 | BBB |
| Lidocaine | National and Kapodistrian University of Athens | P4 | BBB |
| Fentanyl | Aga Khan University | P4 | BBB |
| Nepenthe | Bursa City Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Stanford University | P4 | BBB |
| Pregabalin | Federico II University | P4 | BBB |
| Jnj-54135419 | Beijing Tiantan Hospital | P4 | BBB |
+42 more in the Chronic Pain Syndrome cohort
Other indications for Flurbiprofen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P1 | CC · 40 |
| Tendinitis | — | Unk | D · 30 |
| Arthropathy | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Flurbiprofen in Chronic Pain Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/flurbiprofen-chronic-pain-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →